Concepedia

Proarrhythmic Liability

Proarrhythmic Liability is the inherent potential of a pharmacological agent or physiological insult to disrupt cardiac ion channel function in a manner that promotes the initiation or perpetuation of malignant ventricular arrhythmias.

20

Publications

1.4K

Citations

139

Authors

66

Institutions

Publications per year

2017–2026

7

Parents

Publications

20

Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium

Philip T. Sager, Gary A. Gintant, J. Rick Turner et al. · American Heart Journal · 2013 · 548 citations · Full text

, , +15

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine

Stefan H. Hohnloser, Andreas van de Loo, Frank Baedeker · Journal of the American College of Cardiology · 1995 · 205 citations

, , +16

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment

Kelly C. Chang, Sara Dutta, Gary R. Mirams et al. · Frontiers in Physiology · 2017 · 105 citations · Full text

, , +15

An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes

Wesley L. McKeithan, A. K. Savchenko, Michael S. Yu et al. · Frontiers in Physiology · 2017 · 77 citations · Full text

, , +14

Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic

Jiesheng Kang, Roy J. Vaz, David Rampe · Naunyn-Schmiedeberg s Archives of Pharmacology · 2016 · 66 citations

, , +15

1–5 of 20

Authors

139

  1. DG
    David G. Strauss

    United States Food and Drug Administration, United States

    3 publications · 147 citations

    3

    h-index

  2. JR
    J. Rick Turner

    University of Birmingham, United Kingdom

    2 publications · 558 citations

    2

    h-index

  3. JK
    John Koerner

    United States Food and Drug Administration, United States

    2 publications · 51 citations

    2

    h-index

  4. MK
    Michael K. Pugsley

    University of British Columbia, Canada

    2 publications · 51 citations

    2

    h-index

  5. JG
    Jean‐Michel Guillon

    Sanofi (France), France

    2 publications · 37 citations

    2

    h-index

1–5 of 139

Institutions

66

  1. United States Food and Drug Administration

    Silver Spring, United States

    4 h-index

    7 publications

    695 citations

  2. Center for Drug Evaluation and Research

    Silver Spring, United States

    4 h-index

    14 publications

    1.1K citations

  3. IQVIA (United States)

    Durham, United States

    2 h-index

    2 publications

    558 citations

  4. Stanford University

    Stanford, United States

    2 h-index

    5 publications

    856 citations

  5. Health and Environmental Sciences Institute

    Washington, United States

    2 h-index

    2 publications

    563 citations

  6. Daiichi-Sankyo (Japan)

    Tokyo, Japan

    2 h-index

    4 publications

    63 citations

  7. UCB Pharma (Belgium)

    Brussels, Belgium

    2 h-index

    2 publications

    51 citations

  8. Sanofi (France)

    Paris, France

    2 h-index

    6 publications

    125 citations

1–8 of 66

Venues

  1. 3

    h-index

  2. Frontiers in Physiology

    2 publications · 182 citations

    2

    h-index

  3. PLoS ONE

    2 publications · 51 citations

    2

    h-index

  4. British Journal of Pharmacology

    BJP · 1 publications · 32 citations

    1

    h-index

  5. Drug Information Journal

    DIA · 1 publications · 10 citations

    1

    h-index

1–5